Thanks to natural mutations, more-infectious and potentially deadlier variants of the virus that causes COVID-19 are now racing around the globe and are threatening to turn back the recent progress against the disease due to vaccination.
Thanks to natural mutations, more-infectious and potentially deadlier variants of the virus that causes COVID-19 are now racing around the globe and are threatening to turn back the recent progress against the disease due to vaccination.
Nextech AR Solutions Corp. ("Nextech" or the "Company") (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29) announces its financial and operating results for the fourth quarter and year ended December 31, 2020. This press release contains forward-looking statements. Please refer to our cautionary language on forward-looking statements and the other matters set forth at the end of this press release and the beginning of the Management’s Discussion and Analysis (the "MD&A") for the year ended December 31, 2020. Nextech’s audited financial statements for the year ended December 31, 2020 and notes thereto (the "financial statements"), and the MD&A are available on our website at www.Nextechar.com and are filed on SEDAR at www.sedar.com. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated.
Dozens of entities are targeted over attacks including alleged interference in the 2020 elections.
Chicago city leaders called for calm Thursday and released bodycam videos in the fatal police shooting of Adam Toledo, 13, last month.
Biden officials are working to root out the systematic fraud in unemployment and Paycheck Protection Program claims that plagued the Trump administration’s efforts to boost the economy with coronavirus relief money, Gene Sperling told House committee chairmen privately this week.Why it matters: President Biden just signed another $1.9 trillion of aid into law, with Sperling tapped to oversee its implementation. And the administration is asking Congress to approve another $2.2 trillion for the first phase of an infrastructure package. Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeOrganized efforts to steal the COVID-19 money — or partisan efforts to spin tales of waste — could not only hurt the infrastructure plan but Democrats at the polls in 2022.Congressional Democrats also expect Republicans to repeat the claims of "waste, fraud and abuse" they used against President Obama's 2009 stimulus package.What we're hearing: Crime syndicates have used data readily available online, as well as information from identity theft, to claim or intercept billions in pandemic unemployment benefits during the past year.With more money headed out the door — including six monthly checks of $250 per child ages 6-17, and $300 for each under 6 starting in July — even more theft is possible.Several of the chairmen on the call — which is held at 8:15 a.m. each Wednesday by House Majority Leader Steny Hoyer — said Sperling welcomed their oversight and wanted their help in preventing fraud, Axios was told.Sperling is a veteran Democratic economic aide.The big picture: Democrats know they risk political scandal if stories of graft dominate the coverage of Biden’s signature legislative package.Sperling explained the White House’s commitment to transparency, both before House committees and various agency inspectors general.The Justice Department also has been aggressive in pursuing pandemic fraud cases.Rep. John Yarmuth, the Kentucky Democrat who heads the House Budget Committee, said he was a victim himself of COVID-19 relief fraud.He said Sperling was "very focused" on mitigating abuse during the next round of funding."He basically said that, 'It's on me,'" Yarmouth told Axios.Sperling explained about 40 separate agencies will have some responsibility for implementing the American Rescue Plan.Like this article? Get more from Axios and subscribe to Axios Markets for free.
Mitch Ballock, one of the top 3-point shooters in Creighton history, will not return to the Bluejays in 2021-22. The school confirmed Thursday night that Ballock had signed with an agent and will pursue pro opportunities. Ballock, who is on track to graduate in May, ranks No. 3 on the school 3-point chart with 308, behind Kyle Korver and Ethan Wragge.
Nicholas Burns, a career diplomat, is in the final stages of vetting to serve as President Biden’s ambassador to China, people familiar with the matter tell Axios. Why it matters: Across the administration, there's a consensus the U.S. relationship with China will be the most critical — and consequential — of Biden's presidency. From trade to Taiwan, the stakes are high. Burns could be among the first batch of diplomatic nominees announced in the coming weeks.Get market news worthy of your time with Axios Markets. Subscribe for free.Biden set the table for those nominations Thursday, drawing from the State Department Foreign Service as he named nine career diplomats for postings from Somalia to Senegal.The Foreign Service traditionally supplies 70% of the roughly 190 nominees, and naming career appointees first should reduce internal complaints about political appointments.The remaining spots, typically in coveted Western European capitals and crucial Asian countries, are usually reserved for well-heeled donors, former politicians or policy experts.Between the lines: Burns is a Harvard University professor and former State Department spokesman who capped his Foreign Service career by serving as undersecretary of state for political affairs for President George W. Bush.By sending him to Beijing, Biden would be indicating a preference for a seasoned diplomat instead of a high-wattage politician.The last four U.S. ambassadors to China have all had experience in retail politics, winning elections statewide, either as a governor or senator. Burn's potential nomination was reported by Bloomberg in February. A final decision by the president has not been made. The intrigue: Biden officials also have considered former U.S. Trade Representative Charlene Barshefsky for the post.While not a politician, Barshefsky won Senate confirmation, served in President Clinton’s Cabinet and negotiated with the Chinese on their entry into the World Trade Organization.Go deeper: Biden officials have been urged to nominate a former elected official for Beijing, under the theory the Chinese prefer to deal with a big name who can pick up the phone, cut through the bureaucracy and speak to the president directly. “He needs to appoint a ‘wow-wow’ person to show the world the importance of this relationship,” said former Sen. Max Baucus, the Montana Democrat who served as Obama’s second China ambassador. “It’s also critical that the person is empowered to negotiate on the president’s behalf,” he said. “The ambassadors should not just be a person to deliver messages.” The bottom line: With Biden’s National Security Council and State Department intensely focused on China, the next ambassador’s job could be more about implementing policy instead of creating it. In addition to working with Secretary of State Antony Blinken and national security adviser Jake Sullivan, Biden’s China envoy will also have to coordinate with former Secretary of State John Kerry on climate change.The ambassador also will have to contend with Kurt Campbell, a brash former assistant secretary of state for East Asian and Pacific affairs who is now serving in a newly created “Asia czar” role on the National Security Council.Like this article? Get more from Axios and subscribe to Axios Markets for free.
Everyone wants to go to Disneyland, at least judging from the subsequent long waits for access on the Disney Parks website today, the first day for tickets and reservations in advance of the park’s April 30 reopening. Tickets went on sale at 8 AM. Soon after, a message attempted to soothe any frustration at the […]
Despite bold talk from top administration officials, there's little reason to think the Russia sanctions package President Biden announced Thursday will do anything to alter Russian President Vladimir Putin's behavior or calculus.Why it matters: While it's true some elements of the package — namely, the targeting of Russia's sovereign debt — represent significant punitive measures against Moscow, it leaves plenty of wiggle room for the Russian president.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeWhite House press secretary Jen Psaki defended the action, telling reporters: "We can't predict what the impact will be, but we still believe that when there's unacceptable behavior, we should put consequences in place."Between the lines: Former Secretary of State Rex Tillerson, who had known and dealt with Putin for years while running Exxon Mobil, used to tell colleagues sanctions did little if anything to deter the Russian leader.It's hard to argue against Tillerson's case.The U.S. and its international allies have imposed some form of sanctions against Russia every year since 2014, when Putin's "little green men" first appeared in Ukraine.Since then, Russia has continued to occupy Crimea and eastern Ukraine; propped up the brutal Assad regime in Syria; hacked U.S. and other Western elections; crushed protests at home; and attempted to assassinate dissidents on foreign soil, among other things.Yes, but: Where Thursday's sanctions do break new ground is in the cyber realm.The U.S. government formally accused Russia's Foreign Intelligence Service of the SolarWinds hack and identified its collaborators in painstaking detail, as German security expert Thomas Rid notes in an illuminating Twitter thread.And a ban on U.S. banks directly buying Russian government bonds could create a "broader chilling effect" that will weaken the ruble and have negative implications for inflation and economic growth, a senior administration official told reporters. But the ability for investors to continue buying Russian bonds on the secondary market diminishes the overall effect of the restrictions — reflecting Biden's desire to send a clear message to the Russians without taking it too far.What's missing: Biden notably did not announce sanctions targeting Nord Stream 2, a nearly complete Russian-German pipeline that will bypass Ukraine and deliver Russian gas straight to the European Union. On Thursday, Biden described Nord Stream 2 as a complicated issue that remains "an issue in play," and that he opposes the pipeline. The reality is nobody expected him to sanction an ally — Germany — which is the type of action that might actually stop the pipeline from being completed. What they're saying: "The Ukrainians have not received any assurances from Washington that all possible measures will be taken to stop the pipeline from being built," a source close to Ukrainian President Volodymyr Zelensky told Axios.And the list of sanctioned Russians does not target any oligarchs. Jailed opposition leader Alexei Navalny has said targeting the oligarchs would be more likely to deter Putin because of the vast wealth they hold on his behalf.Like this article? Get more from Axios and subscribe to Axios Markets for free.
April 15 is typically the last day to file your income taxes and pay taxes owed. The Internal Revenue Service pushed that date back to May 17. Now, taxpayers face a unique series of deadlines that may or may not apply, depending on what they do for a living and where they live.
According to statistics published by the British Phonographic Industry (BPI), over a fifth of all singles consumed in the UK last year were classified as rap.
Mackenzie Blackwood (New Jersey Devils) with a Spectacular Goalie Save vs. New York Rangers, 04/15/2021
Anders Bjork (Buffalo Sabres) with a Goal vs. Washington Capitals, 04/15/2021
Around 30+ notable companies are developing Ankylosing Spondylitis therapies. There are currently many new or repurposed drugs in clinical trials being tested to determine clinical benefits in Ankylosing Spondylitis patients.Los Angeles, USA, April 15, 2021 (GLOBE NEWSWIRE) -- New Drugs for Ankylosing Spondylitis Treatment Coming Down the Pipeline: An Updated Clinical Status by DelveInsight Around 30+ notable companies are developing Ankylosing Spondylitis therapies. There are currently many new or repurposed drugs in clinical trials being tested to determine clinical benefits in Ankylosing Spondylitis patients. DelveInsight’s “Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Ankylosing Spondylitis pipeline landscapes. It comprises Ankylosing Spondylitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ankylosing Spondylitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ankylosing Spondylitis pipeline products. Some of the key takeaways of the Ankylosing Spondylitis Pipeline Report Approximately 30+ key companies are developing Ankylosing Spondylitis therapies. These key players are Pfizer, UCB Biopharma, Hetero Biopharma, Amgen, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others have their Ankylosing Spondylitis drug candidates in the different phases of clinical development. Pfizer is one of the companies whose Ankylosing Spondylitis drug candidate is in the most advanced stage (Preregistration). Its drug candidate is Tofacitinib, a medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.UCB Biopharma is developing Bimekizumab, an investigational humanised monoclonal IgG1 antibody that is in Phase III of a clinical trial.In October 2020, Jiangsu HengRui initiated Phase II/III studies to evaluate the efficacy and safety of SHR0302 in patients With Ankylosing Spondylitis (NCT04481139). Get an overview of pipeline landscape @ New Drugs for Ankylosing Spondylitis Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints that can lead to chronic pain and discomfort. The disease can also cause pain, inflammation in other parts of the body, such as the shoulders, hips, ribs, heels and small joints of the hands and feet. In some cases, the eyes are also involved. Ankylosing Spondylitis Emerging Drugs Tofacitinib: Pfizer Tofacitinib, sold under the brand Xeljanz, is a medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. Bimekizumab: UCB Biopharma Bimekizumab is an investigational humanised monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralises IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. For further information, refer to the detailed report @ Ankylosing Spondylitis Pipeline Therapeutics Scope of Ankylosing Spondylitis Pipeline Drug Insight Coverage: Global Major Players: 30+ Key PlayersProminent Players: Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cedilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and many others. Key Drugs Profiles: 30+ ProductsPhases: Ankylosing Spondylitis Therapies Late-stage (Phase III) Ankylosing Spondylitis Therapies Mid-stage (Phase II)Ankylosing Spondylitis Therapies Early-stage (Phase I) Ankylosing Spondylitis Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Molecule Types: Monoclonal AntibodySmall molecule Gene therapyPeptidesPolymer Route of Administration: OralSubcutaneous Intramuscular TopicalIntravenous Product Types: MonotherapyCombinationMono/Combination Key Questions regarding Current Ankylosing Spondylitis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Ankylosing Spondylitis treatment?How many companies are developing therapies for the treatment of Ankylosing Spondylitis? How many are Ankylosing Spondylitis emerging therapies in the early-stage, mid-stage, and late development stages to treat Ankylosing Spondylitis?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Ankylosing Spondylitis market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Ankylosing Spondylitis? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Ankylosing Spondylitis therapies? What are the critical designations that have been granted for the emerging therapies for Ankylosing Spondylitis? How many patents are granted and pending for the emerging therapies to treat Ankylosing Spondylitis? Table of Contents 1Ankylosing Spondylitis Report Introduction2Ankylosing Spondylitis Executive Summary 3Ankylosing Spondylitis Overview4Ankylosing Spondylitis Pipeline Therapeutics5Ankylosing Spondylitis Therapeutic Assessment 6Ankylosing Spondylitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment7Ankylosing Spondylitis Late Stage Products (Registered/Launch)7.1MSB11022: Fresenius Kabi 8Ankylosing Spondylitis Late Stage Products (Preregistration)8.1Tofacitinib: Pfizer 9Ankylosing Spondylitis Late Stage Products (Phase III)9.1Bimekizumab: UCB Biopharma10Ankylosing Spondylitis Mid Stage Products (Phase II/III)10.1Tildrakizumab: Sun Pharma Global11Ankylosing Spondylitis Mid Stage Products (Phase II) 11.1Namilumab: Izana Bioscience 12Ankylosing Spondylitis Early Stage Products (Phase I) 12.1KIN-1901: Kinevant Sciences 13Ankylosing Spondylitis Preclinical Stage Products 13.1Xcimzane: Xbrane Biopharma14Ankylosing Spondylitis Discovery Stage Products 14.1DNA-encoded library (DEL) technology: Dice molecules15Ankylosing Spondylitis Inactive Products16Ankylosing Spondylitis Key Companies 17Ankylosing Spondylitis Key Products18Ankylosing Spondylitis Unmet Needs19Ankylosing Spondylitis Market Drivers and Barriers20 Ankylosing Spondylitis Future Perspectives and Conclusion21Ankylosing Spondylitis Analyst Views22Appendix23About DelveInsight Get a customised pipeline report @ Ankylosing Spondylitis Drugs Pipeline Report Related Reports Ankylosing Spondylitis Epidemiology Forecast DelveInsight's Ankylosing Spondylitis (Bekhterev's Disease) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Ankylosing Spondylitis (Bekhterev's Disease) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Ankylosing Spondylitis Market DelveInsight's Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Hypertrophic Scars Market DelveInsight's Hypertrophic Scar - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the disease. Myc Proto-Oncogene Protein Pipeline Myc Proto-Oncogene Protein Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario. Hepatic Impairment Market DelveInsight's Hepatic Impairment- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview and in-depth understanding of Hepatic Impairment. Pertussis Market DelveInsight's Pertussis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the Pertussis Market. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur email@example.com +1(919)321-6187 www.delveinsight.com
The study also found that around 10% of the young marines who were COVID-19 survivors got a second infection. The previously infected marines who got reinfected had lower antibody levels and fewer neutralizing antibodies, compared to previously infected Marines who did not get reinfected, the study found. "Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralisation activity or immunity against subsequent infection", the study mentioned.
Investigators exhumed another body from a Panama City cemetery Thursday in an attempt to identify the remains of some victims of the 1989 U.S. invasion that removed strongman Manuel Noriega from power. The remains are being subjected to DNA testing in a program that has lifted the hopes of Panamanians who had relatives die or disappear and have lived with unanswered questions about their fate for 30 years. One of the people a court has ordered investigators to search for is Carmen Díaz, a 21-year-old woman who lived in the El Chorrillo district, which was hit by bombs and fires during the invasion.
Radnor, Pennsylvania--(Newsfile Corp. - April 15, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Root, Inc. (NASDAQ: ROOT) ("Root") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired: (a) Root securities between October 28, 2020 and March 8, 2021, both dates inclusive (the "Class Period"); and/or (b) Root Class A common stock issued in connection with Root's initial ...
As storms begin to weaken, severe weather threat warnings or watches won't be issued Thursday night.
Troy Stecher (Detroit Red Wings) with a Goal vs. Chicago Blackhawks, 04/15/2021
Temperatures are expected to reach highs in the lower 40s with scattered showers arriving early, said FOX4 meteorologist Joe Lauria.
Texas handgun owners would no longer need a license or training to carry their weapon in public under a bill that cleared a major vote Thursday over Democrats who railed against loosening gun laws after the 2019 mass shooting at an El Paso Walmart. Texas has more than 1.6 million licensed handgun owners. If approved, Texas would become by far the largest of roughly 20 states that already allow handgun owners to carry their weapons in public without a permit.